𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Extended survival of a HER-2-positive metastatic breast cancer patient with brain metastases also treated with intrathecal trastuzumab

✍ Scribed by Mariantonietta Colozza; Elisa Minenza; Stefania Gori; Daniela Fenocchio; Cristina Paolucci; Cynthia Aristei; Piero Floridi

Publisher
Springer
Year
2008
Tongue
English
Weight
156 KB
Volume
63
Category
Article
ISSN
0344-5704

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Quantitative HER2 protein levels predict
Quantitative HER2 protein levels predict outcome in fluorescence in situ hybridization-positive patients with metastatic breast cancer treated with trastuzumab
✍ Allan Lipton; Wolfgang J. KΓΆstler; Kim Leitzel; Suhail M. Ali; Jeff Sperinde; Jo πŸ“‚ Article πŸ“… 2010 πŸ› John Wiley and Sons 🌐 English βš– 492 KB πŸ‘ 2 views

## Abstract ## BACKGROUND: Only a portion of breast cancer patients currently selected for trastuzumab therapy respond. ## METHODS: Using a novel assay (HERmark) to quantify total human epidermal growth factor receptor 2 (HER2) expression, the authors examined outcomes in 102 trastuzumab‐treated

Survival in patients with brain metastas
Survival in patients with brain metastases from breast cancer : The importance of HER-2 status
✍ April F. Eichler; Irene Kuter; Paula Ryan; Lidia Schapira; Jerry Younger; John W πŸ“‚ Article πŸ“… 2008 πŸ› John Wiley and Sons 🌐 English βš– 183 KB πŸ‘ 2 views

## Abstract ## BACKGROUND Brain metastases (BM) are the most common intracranial tumors in adults. To the authors' knowledge, established prognostic factors for survival after the diagnosis of BM in breast cancer patients do not take into account HER–2 status, which may have increasing relevance i